MGI Tech Singapore Pte, Ltd. (“MGI”), a company committed to building core tools and technology to lead life science, recently entered a research partnership with National Cancer Centre Singapore (“NCCS”) to facilitate comprehensive, multi-dimensional genomic profiling of Asian-prevalent cancers using MGI’s core DNBSEQ™ technology.
FDA approves Avadel’s narcolepsy drug after courts forced Jazz patent delisting
Roughly a month after announcing plans to merge several units under Sumitomo Pharma America this July, the drugmaker is making cuts in Massachusetts. Sumitomo Pharma